The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection
Open accessAbstract
Patients with anti–IFN-γ autoantibodies have impaired IFN-γ signaling, leading to severe disseminated infections with intracellular pathogens, especially nontuberculous mycobacteria. Disease may be severe and progressive, despite aggressive treatment. To address the underlying pathogenic IFN-γ autoantibodies we used the therapeutic monoclonal rituximab (anti-CD20) to target patient B cells. All subjects received between 8 and 12 doses of rituximab within the first year to maintain disease remission. Subsequent doses were given for relapsed infection. We report 4 patients with refractory disease treated with rituximab who had clinical and laboratory evidence of therapeutic response as determined by clearance of infection, resolution of inflammation, reduction of anti–IFN-γ autoantibody levels, and improved IFN-γ signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interferon-γ and interleukin-12 pathway defects and human disease
Dorman, S. E., & Holland, S. M. (2000) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00010-1 · Cited by 336
Self-citation
Cited by
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Hsu, J. T., Keller, M., Kobrynski, L. J., Komarow, H. D., Mazer, B., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.049 · Cited by 791
Adult-Onset Immunodeficiency in Thailand and Taiwan
Browne, S. K., Burbelo, P. D., Chetchotisakd, P., Suputtamongkol, Y., Kiertiburanakul, S., Shaw, P. A., Kirk, J. L., Jutivorakool, K., Zaman, R., Ding, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111160 · Cited by 550
Self-citationEmapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M.-C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911326 · Cited by 534
Immune responses to human fungal pathogens and therapeutic prospects
Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00826-w · Cited by 379
Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts
Henkle, E., & Winthrop, K. L. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.11.002 · Cited by 329
Metadata
- Authors
- Browne, S. K., Zaman, R., Sampaio, E. P., Jutivorakool, K., Rosen, L. B., Ding, L., Pancholi, M. J., Yang, L. M., Priel, D. L., Uzel, G., Freeman, A. F., Hayes, C. E., Baxter, R., Cohen, S. H., & Holland, S. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-04-26
- Volume
- 119
- Issue
- 17
- Pages
- 3933-3939
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2113560700
- Cited by
- 189
- References
- 1
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection. https://app.cochat.ai/papers/10.1182/blood-2011-12-395707
- The paper
- Browne, S. K., Zaman, R., Sampaio, E. P., Jutivorakool, K., Rosen, L. B., Ding, L., Pancholi, M. J., Yang, L. M., Priel, D. L., Uzel, G., Freeman, A. F., Hayes, C. E., Baxter, R., Cohen, S. H., & Holland, S. M. (2012). Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection. Blood. https://doi.org/10.1182/blood-2011-12-395707
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.